These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 22069683)

  • 1. SLT-VEGF reduces lung metastases, decreases tumor recurrence, and improves survival in an orthotopic melanoma model.
    Ackerman R; Backer JM; Backer M; Skariah S; Hamby CV
    Toxins (Basel); 2010 Sep; 2(9):2242-57. PubMed ID: 22069683
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Specific targeting of tumor endothelial cells by a shiga-like toxin-vascular endothelial growth factor fusion protein as a novel treatment strategy for pancreatic cancer.
    Hotz B; Backer MV; Backer JM; Buhr HJ; Hotz HG
    Neoplasia; 2010 Oct; 12(10):797-806. PubMed ID: 20927318
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Shiga-like toxin-VEGF fusion proteins are selectively cytotoxic to endothelial cells overexpressing VEGFR-2.
    Backer MV; Budker VG; Backer JM
    J Control Release; 2001 Jul; 74(1-3):349-55. PubMed ID: 11489517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting endothelial cells overexpressing VEGFR-2: selective toxicity of Shiga-like toxin-VEGF fusion proteins.
    Backer MV; Backer JM
    Bioconjug Chem; 2001; 12(6):1066-73. PubMed ID: 11716701
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting Syndecan-1, a molecule implicated in the process of vasculogenic mimicry, enhances the therapeutic efficacy of the L19-IL2 immunocytokine in human melanoma xenografts.
    Orecchia P; Conte R; Balza E; Pietra G; Mingari MC; Carnemolla B
    Oncotarget; 2015 Nov; 6(35):37426-42. PubMed ID: 26460958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting FGFR/PDGFR/VEGFR impairs tumor growth, angiogenesis, and metastasis by effects on tumor cells, endothelial cells, and pericytes in pancreatic cancer.
    Taeger J; Moser C; Hellerbrand C; Mycielska ME; Glockzin G; Schlitt HJ; Geissler EK; Stoeltzing O; Lang SA
    Mol Cancer Ther; 2011 Nov; 10(11):2157-67. PubMed ID: 21885862
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Suppression of tumor growth and metastasis by simultaneously blocking vascular endothelial growth factor (VEGF)-A and VEGF-C with a receptor-immunoglobulin fusion protein.
    Zhang D; Li B; Shi J; Zhao L; Zhang X; Wang C; Hou S; Qian W; Kou G; Wang H; Guo Y
    Cancer Res; 2010 Mar; 70(6):2495-503. PubMed ID: 20197464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of prostate cancer osteoblastic progression with VEGF121/rGel, a single agent targeting osteoblasts, osteoclasts, and tumor neovasculature.
    Mohamedali KA; Li ZG; Starbuck MW; Wan X; Yang J; Kim S; Zhang W; Rosenblum MG; Navone NM
    Clin Cancer Res; 2011 Apr; 17(8):2328-38. PubMed ID: 21343372
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blocking angiogenesis and tumorigenesis with GFA-116, a synthetic molecule that inhibits binding of vascular endothelial growth factor to its receptor.
    Sun J; Blaskovich MA; Jain RK; Delarue F; Paris D; Brem S; Wotoczek-Obadia M; Lin Q; Coppola D; Choi K; Mullan M; Hamilton AD; Sebti SM
    Cancer Res; 2004 May; 64(10):3586-92. PubMed ID: 15150116
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined MEK and VEGFR inhibition in orthotopic human lung cancer models results in enhanced inhibition of tumor angiogenesis, growth, and metastasis.
    Takahashi O; Komaki R; Smith PD; Jürgensmeier JM; Ryan A; Bekele BN; Wistuba II; Jacoby JJ; Korshunova MV; Biernacka A; Erez B; Hosho K; Herbst RS; O'Reilly MS
    Clin Cancer Res; 2012 Mar; 18(6):1641-54. PubMed ID: 22275507
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of potent VEGF blockade on experimental Wilms tumor and its persisting vasculature.
    Frischer JS; Huang J; Serur A; Kadenhe-Chiweshe A; McCrudden KW; O'Toole K; Holash J; Yancopoulos GD; Yamashiro DJ; Kandel JJ
    Int J Oncol; 2004 Sep; 25(3):549-53. PubMed ID: 15289855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of vascular endothelial growth factor reduces angiogenesis and modulates immune cell infiltration of orthotopic breast cancer xenografts.
    Roland CL; Dineen SP; Lynn KD; Sullivan LA; Dellinger MT; Sadegh L; Sullivan JP; Shames DS; Brekken RA
    Mol Cancer Ther; 2009 Jul; 8(7):1761-71. PubMed ID: 19567820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of vascular endothelial growth factor (VEGF) as a novel approach for cancer therapy.
    Wood JM
    Medicina (B Aires); 2000; 60 Suppl 2():41-7. PubMed ID: 11188930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling.
    He Y; Kozaki K; Karpanen T; Koshikawa K; Yla-Herttuala S; Takahashi T; Alitalo K
    J Natl Cancer Inst; 2002 Jun; 94(11):819-25. PubMed ID: 12048269
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
    Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor effects of synthetic VEGF-receptor binding antagonist, VGA1155.
    Ueda Y; Yamagishi T; Samata K; Hirayama N; Aozuka Y; Tanaka M; Nakaike S; Saiki I
    Anticancer Res; 2005; 25(6B):3973-7. PubMed ID: 16309186
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting SRPK1 to control VEGF-mediated tumour angiogenesis in metastatic melanoma.
    Gammons MV; Lucas R; Dean R; Coupland SE; Oltean S; Bates DO
    Br J Cancer; 2014 Jul; 111(3):477-85. PubMed ID: 25010863
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vascular endothelial growth factor selectively targets boronated dendrimers to tumor vasculature.
    Backer MV; Gaynutdinov TI; Patel V; Bandyopadhyaya AK; Thirumamagal BT; Tjarks W; Barth RF; Claffey K; Backer JM
    Mol Cancer Ther; 2005 Sep; 4(9):1423-9. PubMed ID: 16170035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vascular endothelial growth factor expression promotes the growth of breast cancer brain metastases in nude mice.
    Kim LS; Huang S; Lu W; Lev DC; Price JE
    Clin Exp Metastasis; 2004; 21(2):107-18. PubMed ID: 15168728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
    Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
    Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.